Humoral and cellular immunity induced by antigens adjuvanted with colloidal iron hydroxide

Vaccine

Volumn 17, Issue 9-10, 1999, Pages 1017-1023

  Leibl, Heinz ^a   Tomasits, Regine ^a   Brühl, Peter ^a   Kerschbaum, Astrid ^a   Eibl, Martha M ^b   Mannhalter, Josef W ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adjuvants; Colloidal iron hydroxide; Humoral and cellular immune response; Protective immunity

Indexed keywords

ALUMINUM HYDROXIDE; FERRIC HYDROXIDE; IMMUNOLOGICAL ADJUVANT; TETANUS TOXOID; TICK BORNE ENCEPHALITIS VACCINE; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; EXPERIMENTAL MODEL; HUMORAL IMMUNITY; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TICK BORNE ENCEPHALITIS; VACCINATION; VIRUS ENCEPHALITIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS; COLLOIDS; ENCEPHALITIS VIRUSES, TICK-BORNE; ENCEPHALITIS, TICK-BORNE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROXIDES; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; ORGANIC CHEMICALS; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033525802     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00201-1     Document Type: Article

References (30)

1. Glenny A.T, Pope C.G, Waddington H, Wallace U XXIII: The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol. 29:1926;38-39.
2. Edelman R Vaccine adjuvants. Rev Infect Dis. 2:1980;370-383.
3. Grun J.L, Maurer P.H Different T helper subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol. 121:1989;134-145.
4. Mannhalter J.W, Neychev H.O, Zlabinger G.J, Ahmad R, Eibl M.M Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol. 61:1985;143-151.
5. 4 on purified influenza virus hemagglutinins in man. J Immunol. 100:1968;1139-1140.
6. r=55000 glycoprotein (ZP3). Am J Reprod Immunol. 21:1989;1-8.
7. Butler N.R, Voyce M.A, Burland W.L, Hilton M.L Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants. Br Med J. 1:1969;663-666.
8. White R.G, Coons A.H, Connolly J.M Studies on antibody production. III. The alum granuloma. J Exp Med. 102:1955;73-85.
9. Fawcett H.A, Smith N.P Injection-site granuloma due to aluminium. Arch Dermatol. 120:1984;1318-1322.
10. Hendrick M.J, Goldschmidt M.H, Shofer F.S, Wang Y.Y, Somlyo A.P Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res. 52:1992;5391-5394.
11. Takahashi H, Merli S, Putney S.D, Houghten R, Moss B, Germain R.N, Berzofsky J.A A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. Science. 246:1989;118-121.
12. Gutmann V, Hengge E. Allgemeine und anorganische Chemie. Weinheim: Verlag Chemie GmbH, 1971, p. 108.
13. Bradford M.M A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
14. Mancini G, Carbonara A.O, Heremans J.F Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 2:1965;235-254.
15. Cox W.I, Tartaglia J, Paoletti E Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology. 195:1993;845-850.
16. Kreil T.R, Eibl M.M Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol. 71:1997;2921-2927.
17. Leong K.H, Ramsay A.J, Boyle D.B, Ramshaw I.A Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol. 68:1994;8125-8130.
18. Aprile M.A, Wardlaw A.C Aluminium compounds as adjuvants for vaccines and toxoids in man: A review. Can J Publ Hlth. 57:1966;343.
19. Kunz C. Epidemiology of tick-borne encephalitis and the impact of vaccination on the incident of disease. In: Eibl MM, Huber C, Peter H, Wahn U, editors. Symposium in Immunology VII 1996. Berlin, Heidelberg: Springer Verlag. p. 143-9.
20. Kunz C, Heinz F.X Immunogenicity and reactogenicity of a highly purified vaccine against tick-borne encephalitis. J Med Virol. 6:1980;103.
21. Joo I Mineral carriers as adjuvants. Symp Series Immunobiol Standard. 22:1973;123-130.
22. Newman M.J, Wu J.Y, Gardner B.H, Munroe K.J, Leombruno D, Recchi J, Kensil C.R, Coughlin R.T Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic lymphocyte responses. J Immunol. 148:1992;2357-2362.
23. Nehete P.N, Casement K.S, Arlinghaus R.B, Sastry K.J Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp120. Cell Immunol. 160:1995;217-223.
24. Gupta R.K, Siber G.R Adjuvants for human vaccines: current status, problems and future prospects. Vaccine. 13:1995;1263-1276.
25. Gordon D.M Use of novel adjuvants and delivery systems to improve the humoral and cellular immune response to malaria vaccine candidate antigens. Vaccine. 11:1993;591-593.
26. Germann T, Bongartz M, Dlugonska H, Hess H, Schmitt E, Kolbe L, Kolsch E, Podlaski F.J, Gately M.K, Rude E Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol. 25:1995;823-829.
27. Golding B, Zaitseva M, Golding H The potential for recruiting immune responses toward type 1 or type 2 T-cell help. Am J Trop Med Hyg. 50:1994;33-40.
28. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock K.L Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA. 90:1993;4942-4946.
29. Rock K.L A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today. 17:1996;131-137.
30. Kreuter J Nanoparticles as adjuvants for vaccines. Pharm Biotechnol. 6:1995;463-472.